Moderna (MRNA) Change in Accured Expenses (2018 - 2026)

Moderna (MRNA) has 9 years of Change in Accured Expenses data on file, last reported at $26.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $26.0 million, down 21.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$13.0 million (down 102.55% YoY), and the FY2025 annual result was -$6.0 million, down 107.69% from the prior year.
• Change in Accured Expenses retreated to $26.0 million in Q1 2026 per MRNA's latest filing, from $131.0 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $696.0 million in Q3 2023 and troughed at -$495.0 million in Q1 2023.
• A 5-year average of $46.9 million and a median of $26.0 million in 2026 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 6860.0% in 2023 and fell as far as 1514.29% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $339.0 million in 2022, then tumbled by 92.63% to $25.0 million in 2023, then surged by 1872.0% to $493.0 million in 2024, then tumbled by 73.43% to $131.0 million in 2025, then tumbled by 80.15% to $26.0 million in 2026.
• Business Quant data shows MRNA's Change in Accured Expenses at $26.0 million in Q1 2026, $131.0 million in Q4 2025, and -$112.0 million in Q3 2025.